Forma Therapeutics, Inc.

This study tests a once-daily pill called etavopivat in children (6 months to 18 years) with sickle cell disease. The main goals are to check safety and how the drug works in the body, and to see if it can raise hemoglobin levels and reduce painful crises. About 95 children will …

This study tests a new medicine called etavopivat in 27 children aged 12-16 with sickle cell disease who are at higher risk for stroke. Participants take one daily pill for a year, and doctors use ultrasound to measure blood flow in the brain. The goal is to see if etavopivat can…